Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis.

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis.

Biologicals. 1997 Sep;25(3):289-97. Unique Identifier : AIDSLINE MED/97467281
Vollenbroich D; Ozel M; Vater J; Kamp RM; Pauli G; Max-Volmer-Institut fur Biophysikalische Chemie und Biochemie,; Fachgebiet Biochemie und Molekulare Biolopgie, Technische; Universitat Berlin, Franklinstrasse 29, 10587 Berlin, Germany.

Abstract: The antiviral activity of surfactin, a cyclic lipopeptide antibiotic and biosurfactant produced by Bacillus subtilis, was determined for a broad spectrum of different viruses, Semliki Forest virus (SFV), herpes simplex virus (HSV-1, HSV-2), suid herpes virus (SHV-1), vesicular stomatitis virus (VSV), simian immunodeficiency virus (SIV), feline calicivirus (FCV), murine encephalomyocarditis virus (EMCV). In vitro experiments showed biphasic virus inactivation kinetics for enveloped viruses during treatment. Inactivation of enveloped viruses, especially herpes- and retroviruses, was much more efficient than that of non-enveloped viruses. For those viruses susceptible to its action, surfactin was active at 25 microM in medium containing 5% fetal calf serum (FCS). Concentrations up to 80 microM of surfactin led to a titre reduction of >4.4 log10 CCID50/ml for HSV-1 in 15 min and for SIV and VSV in 60 min. The inactivation rate increased linearly with the incubation temperature by a factor 2.4/10 degrees C and logarithmically with the concentration. Serum components, probably proteins and/or lipids, influence the effective surfactin concentration. A disruption of the viral lipid membrane and partially of the capsid was observed by electron microscopy. These findings suggest that the antiviral action, postulated also in other investigations, seems to be due to a physicochemical interaction of the membrane-active surfactant with the virus lipid membrane. Surfactin may be useful for application in virus safety enhancement of biotechnological and pharmaceutical products. Copyright 1997 The International Association of Biological Standardization.

Keywords: Animal Antiviral Agents/*PHARMACOLOGY Bacillus subtilis Bacterial Proteins/*PHARMACOLOGY Cats Cell Division/DRUG EFFECTS Cells, Cultured Cercopithecus aethiops Hamsters Herpesvirus 1, Suid/*DRUG EFFECTS Human Lipoproteins/*PHARMACOLOGY Mice Microbial Sensitivity Tests Support, Non-U.S. Gov't Vero Cells Viral Envelope Proteins/METABOLISM JOURNAL ARTICLE
980228
M9820737

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .